GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
January 31, 2024 at 09:47 AM EST
The RSV shot, called Abrysvo, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.
